lobbying_activities: 2973492

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2973492	2a123ed9-82f0-4077-8a9e-d314107e6d31	Q1	MARSHALL & POPP, LLC	401105121	AMGEN USA INC.	2023	first_quarter	PHA	Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2023-04-19T20:41:16-04:00